pfrank1978 / iStockphoto.com
Governments around the world are urged to respect TRIPS and administer a stable, harmonised IP system that incentivises the development of genetic technologies, say Claire Baldock, Michael Christie and Jürgen Meier, members of the AIPPI sub-committee for biotechnology and plant varieties.
During its World Congress in Sydney last year, the International Association for the Protection of Intellectual Property (AIPPI) passed an important resolution on gene patenting, which addresses the lack of international harmonisation regarding the patent eligibility of genetic material.
With an overwhelming majority of about 90% of the votes, the AIPPI delegates adopted the resolution, urging governments and patent authorities to treat nucleic acids as they would other chemical compounds.
The resolution also urged governments to implement the necessary legislative measures to ensure that genetic materials, when isolated from nature or artificially synthesised, constitute patent-eligible subject matter.
AIPPI, harmonisation, Claire Baldock, Jürgen Meier, Michael Christie